Načítá se...

Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multi-k...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biol Blood Marrow Transplant
Hlavní autoři: Baird, Kristin, Comis, Leora E., Joe, Galen O., Steinberg, Seth M., Hakim, Fran T., Rose, Jeremy J., Mitchell, Sandra A., Pavletic, Steven Z., Figg, William D., Yao, Lawrence, Flanders, Kathleen C., Takebe, Naoko, Sarantopoulos, Stefanie, Booher, Susan, Cowen, Edward W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425991/
https://ncbi.nlm.nih.gov/pubmed/25771402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.03.006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!